MA33467B1 - Promédicaments comprenant un conjugué insuline-lieur - Google Patents

Promédicaments comprenant un conjugué insuline-lieur

Info

Publication number
MA33467B1
MA33467B1 MA34582A MA34582A MA33467B1 MA 33467 B1 MA33467 B1 MA 33467B1 MA 34582 A MA34582 A MA 34582A MA 34582 A MA34582 A MA 34582A MA 33467 B1 MA33467 B1 MA 33467B1
Authority
MA
Morocco
Prior art keywords
insulin
binding
drugs include
include insulin
primary drugs
Prior art date
Application number
MA34582A
Other languages
Arabic (ar)
English (en)
Inventor
Harald Rau
Felix Cleemann
Ulrich Hersel
Silvia Kaden-Vagt
Torben Lessmann
Thomas Wegge
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA33467B1 publication Critical patent/MA33467B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN PROMÉDICAMENT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, CONTENANT UN CONJUGUÉ D-L ASSOCIANT UNE SÉQUENCE DE LIAISON ET DE L'INSULINE, D REPRÉSENTANT LA FRACTION INSULINE ET -L LA FRACTION SÉQUENCE DE LIAISON NON BIOLOGIQUEMENT ACTIVE -L1 DE FORMULE (I), LE POINTILLÉ INDIQUANT LA LIAISON À L'UN DES GROUPES AMINÉS DE L'INSULINE PAR FORMATION D'UNE LIAISON AMIDE. L'INVENTION CONCERNE, EN OUTRE, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS PROMÉDICAMENTS, AINSI QUE LEUR UTILISATION EN TANT QUE MÉDICAMENTS À DES FINS DE TRAITEMENT OU DE PRÉVENTION DE MALADIES OU D'AFFECTIONS POUVANT ÊTRE TRAITÉES PAR L'INSULINE.
MA34582A 2009-07-31 2010-07-30 Promédicaments comprenant un conjugué insuline-lieur MA33467B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09167027 2009-07-31
EP09174525 2009-10-29
EP09179336 2009-12-15
EP09179818 2009-12-18
PCT/EP2010/061159 WO2011012718A1 (fr) 2009-07-31 2010-07-30 Promédicaments contenant un conjugué associant une séquence de liaison et de l'insuline

Publications (1)

Publication Number Publication Date
MA33467B1 true MA33467B1 (fr) 2012-07-03

Family

ID=42670465

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34582A MA33467B1 (fr) 2009-07-31 2010-07-30 Promédicaments comprenant un conjugué insuline-lieur

Country Status (21)

Country Link
US (2) US9138462B2 (fr)
EP (1) EP2459228B1 (fr)
JP (1) JP5738291B2 (fr)
KR (1) KR20120089843A (fr)
CN (1) CN102548583B (fr)
AU (1) AU2010277559B2 (fr)
BR (1) BR112012002168A2 (fr)
CA (1) CA2769340C (fr)
CL (1) CL2012000248A1 (fr)
CO (1) CO6491083A2 (fr)
CR (1) CR20120018A (fr)
IL (1) IL217778A (fr)
MA (1) MA33467B1 (fr)
MX (1) MX2012001399A (fr)
NI (1) NI201200012A (fr)
NZ (1) NZ598021A (fr)
PE (1) PE20120918A1 (fr)
SG (1) SG178193A1 (fr)
TN (1) TN2012000011A1 (fr)
WO (1) WO2011012718A1 (fr)
ZA (1) ZA201200223B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010782A (es) * 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
MA33466B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Composition d'insuline à longue duree d'action
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
JP6392123B2 (ja) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 糖尿病治療のためのｃｔｐ系インスリンアナローグ
EP3395358B1 (fr) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Dimères d'un analogue d'insuline
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MY178680A (en) 2012-10-11 2020-10-20 Ascendis Pharma As Hydrogel prodrugs
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
US20180042996A1 (en) * 2013-10-08 2018-02-15 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-Linked IL-1ra Prodrug
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086728A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2016049190A1 (fr) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Conjugués d'insuline-incrétines
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
KR102786270B1 (ko) 2016-03-01 2025-03-24 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
WO2018013673A1 (fr) 2016-07-13 2018-01-18 Reform Biologics, Llc Excipients stabilisants pour formulations de protéines thérapeutiques
KR20230170810A (ko) 2016-09-29 2023-12-19 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
CN109789189B (zh) 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
CA3037444A1 (fr) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Schema posologique incrementiel dans des composes de pth a liberation controlee
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11590237B2 (en) 2017-05-18 2023-02-28 Merck Sharp & Dohme Llc Pharmaceutical formulation comprising incretin-insulin conjugates
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
BR112021014581A2 (pt) 2019-02-11 2021-12-14 Ascendis Pharma Bone Diseases As Formulações farmacêuticas líquidas de conjugados de pth
EP3986477A1 (fr) * 2019-06-21 2022-04-27 Ascendis Pharma A/S CONJUGUÉS DE COMPOSÉS AZOTÉS HÉTÉROAROMATIQUES DONNEURS DE PAIRES D'ÉLECTRONS pi
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
US20230346949A1 (en) * 2019-12-10 2023-11-02 Sanofi A method of forming a conjugate of a sulfonamide and a polypeptide
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
FI913037A7 (fi) 1988-12-23 1991-06-20 Novo Nordisk As Ihmisen insuliinianalogit
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
WO1993017669A1 (fr) 1992-02-28 1993-09-16 Board Of Regents, The University Of Texas System Hydrogels biodegradables, polymerisables utilises en tant que materiaux en contact avec des tissus et excipients a liberation controlee
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE19626762A1 (de) 1996-07-03 1998-01-08 Basf Ag Enzymatisch spaltbare Linker für Festphasensynthesen
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
EP1032587B2 (fr) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1037649B1 (fr) 1997-12-17 2009-09-30 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
EP1117444A2 (fr) 1998-10-09 2001-07-25 The University Of Michigan Hydrogels et supports polymeres solubles dans l'eau pour administration de medicaments
WO2000044808A1 (fr) 1999-02-01 2000-08-03 Hubbell Jeffrey A Biomateriaux formes par reaction d'addition nucleophile a des groupes non satures conjugues
DK1105409T3 (da) 1999-05-17 2006-07-03 Conjuchem Inc Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
CA2376714A1 (fr) 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derives du chitosane et du poly(ethylene glycol) ou de polymeres apparentes
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
BR0107942A (pt) 2000-01-28 2004-01-06 Infimed Therapeutics Inc Polìmeros de proteìna de liberação lenta
US6884778B2 (en) 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4841066B2 (ja) 2000-09-01 2011-12-21 ライスユニバーシティ 酸化窒素生成ヒドロゲル物質
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1243276A1 (fr) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Prodrogues activables à séparateurs allongés et multiples
JP4340067B2 (ja) 2001-04-23 2009-10-07 ウィスコンシン アルムニ リサーチ ファウンデイション 二機能性改変ハイドロゲル
AR033903A1 (es) 2001-05-21 2004-01-07 Inhale Therapeutic Syst Una composicion de insulina modificada quimicamente para la administracion pulmonar
DE60132094T3 (de) 2001-10-26 2012-02-02 Octoplus Polyactive Sciences B.V. Verfahren zur Herstellung von gereinigten Partikeln
US6960298B2 (en) 2001-12-10 2005-11-01 Nanogen, Inc. Mesoporous permeation layers for use on active electronic matrix devices
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003226166A1 (en) 2002-04-04 2003-10-20 Enzon, Inc. Polymeric acyl derivatives of indoles
DE10221457A1 (de) 2002-05-15 2003-11-27 Behr Gmbh & Co Wärmeübertrager und Verfahren zu seiner Herstellung
EP1531868A2 (fr) 2002-06-03 2005-05-25 Alnis Biosciences, Inc. Agents therapeutiques contenant des nano-polymeres
EP1529055A4 (fr) 2002-06-10 2005-11-30 Merck & Co Inc Molecule d'acide nucleique isolee codant une proteine de type moteur associee a un centromere, et ses utilisations
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
EP1525890A1 (fr) 2003-10-02 2005-04-27 Complex Biosystems GmbH Complexes protéine-protéophore
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
EP1586334A1 (fr) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugés avec PEG
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1625856A1 (fr) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel conjugé polymèrique d'une prodrogue
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006038462A1 (fr) 2004-10-01 2006-04-13 Kyushu University, National University Corporation Cellule novatrice de production de stéroïde
DE102004051715A1 (de) 2004-10-23 2005-06-30 Clariant Gmbh Flüssigwaschmittel enthaltend Farbfixiermittel
US20060115865A1 (en) 2004-10-25 2006-06-01 Anlong Ouyang Lamotrigine analogs
US7678551B2 (en) 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US7407117B2 (en) 2004-10-28 2008-08-05 Meadwestvaco Calmar, Inc. Liquid sprayer assembly
JP2006163996A (ja) 2004-12-09 2006-06-22 Evolium Sas 行動履歴に基づくプッシュ型の情報提供システム
AU2005323534A1 (en) 2005-01-05 2006-07-13 Philip S. Portoghese Analgesic conjugates
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007082088A2 (fr) 2006-01-12 2007-07-19 Histogenics Corporation Procede de reparation et de reconstruction de ligaments ou de tendons rompus ou de traitement de lesions ligamentaires et tendineuses
EP1840152B1 (fr) 2006-03-31 2009-07-08 Sony Deutschland Gmbh Procédé de production d'un gel polymèrique réticulé
WO2007140312A2 (fr) 2006-05-25 2007-12-06 The General Hospital Corporation Agents anti-réticulation et procédés permettant de bloquer la réticulation de préparations d'hydrogel injectables
ES2542146T3 (es) * 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
US20080187568A1 (en) 2007-02-06 2008-08-07 Sawhney Amarpreet S Polymerization with precipitation of proteins for elution in physiological solution
US20080220047A1 (en) 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
WO2008116913A2 (fr) 2007-03-28 2008-10-02 Novo Nordisk A/S Composés peptidiques à pégylation biodégradable transitoire
DK2136850T3 (da) 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
EP2017288A1 (fr) * 2007-07-16 2009-01-21 Novo Nordisk A/S Analogues de l'insuline pégylés, stabilisés à la protéase
EP2170945A1 (fr) * 2007-07-16 2010-04-07 Novo Nordisk A/S Analogues pegylés de l'insuline, stabilisés vis-à-vis des protéases
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2237799B1 (fr) 2008-02-01 2019-04-10 Ascendis Pharma A/S Promédicament comprenant un linker auto-clivable
WO2009102952A2 (fr) 2008-02-13 2009-08-20 Hyperbranch Medical Technology, Inc. Hydrogels à base de polyalkylèneimines réticulées à taux de dégradation ajustable
JP2011518881A (ja) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
PT3050576T (pt) 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
MX2011008963A (es) 2009-03-05 2012-02-01 Ascendis Pharma As Profarmacos portadores de interferon alfa.
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
BR112012002280B1 (pt) 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
MA33466B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Composition d'insuline à longue duree d'action
CN102686245B (zh) 2009-10-29 2015-09-30 阿森迪斯药物股份有限公司 可生物降解水凝胶的消毒
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine

Also Published As

Publication number Publication date
PE20120918A1 (es) 2012-08-14
CN102548583A (zh) 2012-07-04
JP2013500951A (ja) 2013-01-10
US20150258207A1 (en) 2015-09-17
CO6491083A2 (es) 2012-07-31
CA2769340A1 (fr) 2011-02-03
NI201200012A (es) 2012-08-08
RU2012107542A (ru) 2013-09-10
SG178193A1 (en) 2012-03-29
AU2010277559B2 (en) 2016-08-11
BR112012002168A2 (pt) 2016-05-31
TN2012000011A1 (en) 2013-09-19
KR20120089843A (ko) 2012-08-14
IL217778A (en) 2015-10-29
IL217778A0 (en) 2012-03-29
EP2459228A1 (fr) 2012-06-06
CN102548583B (zh) 2015-04-22
CA2769340C (fr) 2018-09-11
AU2010277559A1 (en) 2012-02-23
JP5738291B2 (ja) 2015-06-24
US9138462B2 (en) 2015-09-22
WO2011012718A1 (fr) 2011-02-03
EP2459228B1 (fr) 2020-03-04
CL2012000248A1 (es) 2012-08-31
CR20120018A (es) 2012-04-18
ZA201200223B (en) 2012-09-26
US20120184489A1 (en) 2012-07-19
MX2012001399A (es) 2012-03-21
US9457066B2 (en) 2016-10-04
NZ598021A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
MA35576B1 (fr) Nouveaux composés
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA38837B1 (fr) Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
BRPI0414581A (pt) derivados de benzimidazol: preparação e aplicações farmacêuticas
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34474B1 (fr) Agonistes de gpr40
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
BR112014023384A8 (pt) inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos.
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA35638B1 (fr) 2-thiopyrimidinones
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA38556A1 (fr) Inhibiteurs de bace1
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1